<DOC>
	<DOCNO>NCT00244387</DOCNO>
	<brief_summary>Male female patient age â‰¥ 30 year advanced stage idiopathic Parkinson 's disease , well control exist levodopa take part research study approximately 82 site Europe , Israel , South Africa , Australia new Zealand . The purpose study evaluate effectiveness , safety tolerability rotigotine patch ( SPM 962 ) individual patient 's optimal dose period 4 month Each patient qualify choose participate study receive either rotigotine , pramipexole , placebo gradually increase dos period 7 week , maintain optimal dose 4 month . The study clinic visit include medical history physical exam , ECG , blood urine sample collection , completion various questionnaire , completion diary record severity Parkinson 's symptom . Patients complete study may enroll extension trial receive active study drug .</brief_summary>
	<brief_title>Rotigotine Patch Subjects With Advanced Stage , Idiopathic Parkinson 's Disease Who Are Not Well Controlled Levodopa</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Advanced stage idiopathic Parkinson 's disease Well control levodopa</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>advanced stage idiopathic Parkinson 's disease</keyword>
</DOC>